3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
2
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Metastatic HER2-positive Breast Cancer
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Adenocarcinoma Of Esophagus
1
Interventions
Doxorubicin
15
pembrolizumab
12
Surgical Procedures, Operative
8
Cyclophosphamide
8
Blood Specimen Collection
8
Ifosfamide
7
Gemcitabine
7
Surveys and Questionnaires
6
Nivolumab
6
Trabectedin
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
atezolizumab
4
Temozolomide
4
Specimen Handling
4
Radiation Dose Hypofractionation
4
Biopsy
4
pazopanib
3
liposomal doxorubicin
3
fludarabine
3
cabozantinib
3
anlotinib
3
Radiation
3
Observation
3
Docetaxel
3
Dacarbazine
3
trastuzumab deruxtecan
2
toripalimab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma
×
zanidatamab
×
Clear all
NCT07192068
2025-12-19
AcSé HER2
UNICANCER
Phase 2
Recruiting
105 enrolled